Intangible Assets

ARMP does not appear to have a durable proprietary IP or regulatory asset base that clearly supports pricing power versus peers, so any advantage is likely limited and contestable.

The absence of disclosed 5-year margin and ROIC history in the provided metrics makes it difficult to evidence persistent intangible-driven economics, which weakens peer-relative confidence.

Compared with stronger specialty pharma peers that can defend exclusivity through deeper patent estates or approved-label differentiation, ARMP’s moat from intangibles looks materially thinner.

No evidence in the provided data indicates brand strength or clinical differentiation that would reliably sustain retention or margins over 5–10 years.

Switching Costs

The provided metrics do not indicate customer lock-in, and the very low asset turnover suggests the business is not demonstrating the kind of recurring, embedded usage that usually creates switching costs.

ARMP appears to face a peer set where buyers can substitute alternative therapies or suppliers, so retention is unlikely to depend on a unique integrated workflow or platform.

Negative TTM ROIC implies the company is not yet converting capital into durable customer relationships, which is inconsistent with meaningful switching-cost protection.

Compared with peers that benefit from formulary position, physician habit, or platform integration, ARMP shows little evidence of structural switching friction.

Network Effects

ARMP does not show evidence of a user, data, or ecosystem flywheel that would make each additional customer more valuable to others, so network effects appear absent.

In pharmaceuticals, network effects are generally limited unless a company controls a platform or data network, and the provided information does not support that for ARMP.

Unlike peers with scale-driven real-world evidence loops or distribution ecosystems, ARMP’s economics do not indicate compounding adoption benefits.

The available metrics provide no sign that market share gains would automatically reinforce pricing power or retention.

Cost Advantage

ARMP’s negative TTM ROIC and low asset turnover do not indicate a cost structure that is superior to peers, which limits evidence of a durable cost advantage.

A company with a true cost edge should usually show stronger capital efficiency than competitors, but the provided metrics point to the opposite.

Compared with larger peers that can spread R&D, manufacturing, or commercialization costs across broader revenue bases, ARMP does not appear to have scale-based unit-cost leverage.

No data provided suggests ARMP can underprice peers while preserving margins, so cost advantage looks weak and not durable.

Efficient Scale

ARMP does not appear to operate in a niche where one or two players can efficiently serve the market and deter entry, so efficient-scale protection looks limited.

The provided metrics do not show the kind of high, stable profitability that usually accompanies a protected niche with constrained competitive capacity.

Compared with peers that benefit from concentrated market structures or specialized distribution, ARMP does not show evidence of industry capacity discipline that would preserve margins.

Low asset turnover and negative ROIC suggest the business is not yet exploiting a scale position that would make entry uneconomic for rivals.

Overall Score

ARMP’s moat appears weak versus peers because the provided evidence does not support durable intangible assets, switching costs, network effects, cost advantage, or efficient-scale protection, and the negative TTM ROIC further suggests limited pricing power and retention durability over the next 5–10 years.